financetom
TKLF
financetom
/
Consumer Staples
/
TKLF
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Yoshitsu Co., LtdTKLF
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Yoshitsu Co., Ltd engages in the retail and wholesale of beauty, health, and other products.

It offers beauty products, such as cosmetics comprising of foundation, powder, concealer, makeup remover, eyeliner, eye shadow, brow powder, brow pencil, mascara, lip gloss, lipstick, and nail polish; skin care products consisting of facial cleanser, whitening products, sun block, moisturizer, facial mask, eye mask, eye gel, and exfoliating; and cosmetic applicators, such as brush, puff, curler, hair iron, and shaver products.

The company also provides body care products, such as shampoo, conditioner, and body wash; and fragrance products consisting of perfume and cologne for women and men.

In addition, the company provides facial wash, firming lotion, astringent, and moisturizer products for men; and lip balm, lotion, shampoo, soap, and essence oil for children.

Further, the company offers OTC drugs for the treatment of common ailments, such as colds, headaches, stomach pain, cough, and eye strains, as well as medical supplies and devices, including bandages, masks, thermometers, disinfectant sprays, eye masks, contact lens, and contact lens cleaners and solutions.

Additionally, the company provides vitamins, minerals, fiber supplements, nutritional yeast, dietary products, and other nutritional supplements; bedding and bath products, and car supplies; and food, alcoholic beverages, and miscellaneous products.

It directly operates physical stores in Japan and Hong Kong; online stores in Japan, China, and Korea; and franchise stores in the United States, Canada, and the United Kingdom, as well as wholesale customers in Japan, China, the United States, and Canada.

The company was incorporated in 2006 and is headquartered in Tokyo, Japan.

Latest News >
China leading generative AI patents race, UN report says
China leading generative AI patents race, UN report says
Jul 3, 2024
GENEVA, July 3 (Reuters) - China is far ahead of other countries in generative AI inventions like chatbots, filing six times more patents than its closest rival the United States, U.N. data showed on Wednesday. Generative AI, which produces text, images, computer code and even music from existing information, is exploding with more than 50,000 patent applications filed in the...
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Jul 3, 2024
04:15 AM EDT, 07/03/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Wednesday the European Commission has approved Dupixent as an additional maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, or COPD, a respiratory disease that damages the lungs. The decision marks the first Dupixent approval worldwide for COPD patients, the companies...
Futu's Wealth Business Surpasses $10 Billion in Assets Under Management
Futu's Wealth Business Surpasses $10 Billion in Assets Under Management
Jul 3, 2024
04:16 AM EDT, 07/03/2024 (MT Newswires) -- Futu Holdings ( FUTU ) said early Wednesday its wealth management business surpassed $10 billion in assets under management. The company also said its fully-owned subsidiary, Moomoo Securities Malaysia, recently received approval from the Federation of Investment Managers Malaysia to distribute wealth management products in the country. Price: 65.89, Change: -0.13, Percent Change:...
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
Jul 3, 2024
In a significant development in the battle against Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly ( LLY ) and Company’s Alzheimer’s treatment, “Kisunla.” What Happened: As per the official press release on Tuesday, Kisunla (donanemab-azbt), a once-monthly IV infusion injection, is intended for adults in the early symptomatic stages of Alzheimer’s disease, including those...
Copyright 2023-2025 - www.financetom.com All Rights Reserved